$DVA
DAVITA INC.

2024 Q4 Form 10-Q Financial Statement

#000092706624000179 Filed on October 29, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $3.264B
YoY Change 4.56%
Cost Of Revenue $2.152B
YoY Change 4.09%
Gross Profit $1.112B
YoY Change 5.47%
Gross Profit Margin 34.06%
Selling, General & Admin $393.5M
YoY Change 4.42%
% of Gross Profit 35.4%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $187.0M
YoY Change -0.77%
% of Gross Profit 16.82%
Operating Expenses $580.5M
YoY Change 2.7%
Operating Profit $534.9M
YoY Change 7.85%
Interest Expense -$130.9M
YoY Change 44.05%
% of Operating Profit -24.47%
Other Income/Expense, Net -$16.78M
YoY Change -14.61%
Pretax Income $373.4M
YoY Change -1.26%
Income Tax $77.67M
% Of Pretax Income 20.8%
Net Earnings $214.7M
YoY Change -12.95%
Net Earnings / Revenue 6.58%
Basic Earnings Per Share $2.56
Diluted Earnings Per Share $2.50
COMMON SHARES
Basic Shares Outstanding 82.00M shares 83.90M shares
Diluted Shares Outstanding 85.80M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.126B
YoY Change 122.24%
Cash & Equivalents $1.071B
Short-Term Investments $54.84M
Other Short-Term Assets $184.9M
YoY Change -1.03%
Inventory $129.0M
Prepaid Expenses
Receivables $2.267B
Other Receivables $359.5M
Total Short-Term Assets $4.037B
YoY Change 28.76%
LONG-TERM ASSETS
Property, Plant & Equipment $2.940B
YoY Change -5.1%
Goodwill $7.228B
YoY Change 1.97%
Intangibles $197.9M
YoY Change 6.72%
Long-Term Investments $464.3M
YoY Change -23.97%
Other Assets $219.0M
YoY Change -27.53%
Total Long-Term Assets $13.47B
YoY Change -2.37%
TOTAL ASSETS
Total Short-Term Assets $4.037B
Total Long-Term Assets $13.47B
Total Assets $17.50B
YoY Change 3.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $488.2M
YoY Change 12.13%
Accrued Expenses $1.211B
YoY Change 4.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $296.3M
YoY Change 172.9%
Total Short-Term Liabilities $2.944B
YoY Change 16.0%
LONG-TERM LIABILITIES
Long-Term Debt $9.260B
YoY Change 11.77%
Other Long-Term Liabilities $183.0M
YoY Change -1.03%
Total Long-Term Liabilities $183.0M
YoY Change -1.03%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.944B
Total Long-Term Liabilities $183.0M
Total Liabilities $15.28B
YoY Change 8.37%
SHAREHOLDERS EQUITY
Retained Earnings $1.275B
YoY Change 78.27%
Common Stock $295.7M
YoY Change -46.5%
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.022B
YoY Change
Treasury Stock Shares
Shareholders Equity $386.7M
YoY Change
Total Liabilities & Shareholders Equity $17.50B
YoY Change 3.4%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $214.7M
YoY Change -12.95%
Depreciation, Depletion And Amortization $187.0M
YoY Change -0.77%
Cash From Operating Activities $810.4M
YoY Change 22.58%
INVESTING ACTIVITIES
Capital Expenditures $139.0M
YoY Change 1.63%
Acquisitions
YoY Change
Other Investing Activities -$7.445M
YoY Change 148.75%
Cash From Investing Activities -$146.5M
YoY Change 4.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -7.858M
YoY Change -98.01%
NET CHANGE
Cash From Operating Activities 810.4M
Cash From Investing Activities -146.5M
Cash From Financing Activities -7.858M
Net Change In Cash 656.1M
YoY Change 417.5%
FREE CASH FLOW
Cash From Operating Activities $810.4M
Capital Expenditures $139.0M
Free Cash Flow $671.4M
YoY Change 28.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
us-gaap Revenues
Revenues
9520867000 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
DAVITA INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
51-0354549
dei Entity Address City Or Town
EntityAddressCityOrTown
Denver,
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80202
dei City Area Code
CityAreaCode
720
dei Local Phone Number
LocalPhoneNumber
631-2100
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
DVA
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
82000000.0 shares
CY2024Q3 dva Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts
RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts
3138561000 usd
CY2023Q3 dva Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts
RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts
2951950000 usd
dva Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts
RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts
9141195000 usd
dva Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts
RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts
8602669000 usd
CY2023Q3 us-gaap Other Income
OtherIncome
169382000 usd
us-gaap Other Income
OtherIncome
379672000 usd
us-gaap Other Income
OtherIncome
391731000 usd
CY2024Q3 us-gaap Revenues
Revenues
3263590000 usd
CY2023Q3 us-gaap Revenues
Revenues
3121332000 usd
us-gaap Revenues
Revenues
9520867000 usd
us-gaap Revenues
Revenues
8994400000 usd
CY2024Q3 dva Patient Care Costs
PatientCareCosts
2151875000 usd
CY2023Q3 dva Patient Care Costs
PatientCareCosts
2067315000 usd
dva Patient Care Costs
PatientCareCosts
6373150000 usd
dva Patient Care Costs
PatientCareCosts
6181348000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
393534000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
376883000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1123859000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1072513000 usd
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
187014000 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
188423000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
549758000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
550166000 usd
CY2024Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3711000 usd
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
7228000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
15874000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
22502000 usd
CY2023 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
25723000 usd
us-gaap Interest And Debt Expense
InterestAndDebtExpense
331748000 usd
us-gaap Interest And Debt Expense
InterestAndDebtExpense
302361000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-16780000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-19650000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
373434000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
378209000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
77674000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
224479000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
185536000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
246632000 usd
us-gaap Net Income Loss
NetIncomeLoss
677013000 usd
us-gaap Net Income Loss
NetIncomeLoss
540870000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.95
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93317000 shares
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2501364000 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
197854000 usd
CY2024Q3 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
430483000 usd
CY2024Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
33844000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
218956000 usd
CY2024Q3 us-gaap Goodwill
Goodwill
7227630000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
488244000 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
927530000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
806149000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
404540000 usd
CY2024Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
296255000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2943986000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2237135000 usd
CY2024Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
9260331000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
183030000 usd
CY2024Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
659581000 usd
CY2024Q3 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
1633011000 usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
90132000 shares
us-gaap Share Based Compensation
ShareBasedCompensation
75392000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-53713000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-17767000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-24159000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1633000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
175643000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-118148000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-290000 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Entity Central Index Key
EntityCentralIndexKey
0000927066
dei Entity Address Address Line1
EntityAddressAddressLine1
2000 16th Street
dei Entity Shell Company
EntityShellCompany
false
dei Entity File Number
EntityFileNumber
1-14106
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
82624000 shares
CY2024Q3 us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain
BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
0 usd
CY2023Q3 us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain
BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
0 usd
us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain
BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
35147000 usd
us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain
BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
0 usd
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
2728712000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
2625393000 usd
us-gaap Costs And Expenses
CostsAndExpenses
7995746000 usd
us-gaap Costs And Expenses
CostsAndExpenses
7781525000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
495939000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
1525121000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
1212875000 usd
CY2024Q3 us-gaap Interest And Debt Expense
InterestAndDebtExpense
134583000 usd
CY2023Q3 us-gaap Interest And Debt Expense
InterestAndDebtExpense
98080000 usd
CY2024Q3 dva Debt Prepayment Extinguishment And Modification Costs
DebtPrepaymentExtinguishmentAndModificationCosts
10081000 usd
CY2023Q3 dva Debt Prepayment Extinguishment And Modification Costs
DebtPrepaymentExtinguishmentAndModificationCosts
0 usd
dva Debt Prepayment Extinguishment And Modification Costs
DebtPrepaymentExtinguishmentAndModificationCosts
19813000 usd
dva Debt Prepayment Extinguishment And Modification Costs
DebtPrepaymentExtinguishmentAndModificationCosts
7962000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-56900000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14525000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1116660000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
888027000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
68848000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
215168000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
161621000 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
295760000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
309361000 usd
us-gaap Profit Loss
ProfitLoss
901492000 usd
us-gaap Profit Loss
ProfitLoss
726406000 usd
CY2024Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
81072000 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
62729000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
214688000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.56
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.70
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
7.86
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.50
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.80
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83721000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91322000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86123000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90937000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94041000 shares
CY2024Q3 us-gaap Profit Loss
ProfitLoss
295760000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
309361000 usd
us-gaap Profit Loss
ProfitLoss
901492000 usd
us-gaap Profit Loss
ProfitLoss
726406000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
-21576000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
6996000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
-2340000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
28305000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
1870000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
21198000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
45539000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
55895000 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
56202000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-47644000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-62371000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
27878000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-61846000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-110250000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
288000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
328516000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
247515000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
791242000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
726694000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
81072000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
62729000 usd
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
224479000 usd
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
185536000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
247444000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
184786000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
566763000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
541158000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1070775000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
380063000 usd
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
87869000 usd
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
84571000 usd
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
20996000 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
11610000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2267365000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1986856000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
128999000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
143105000 usd
CY2024Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
359485000 usd
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
422669000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
96989000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
102645000 usd
CY2024Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
4522000 usd
CY2023Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
6387000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
4037000000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
3137906000 usd
CY2024Q3 us-gaap Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
6174254000 usd
CY2023Q4 us-gaap Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
5759514000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3073533000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2418350000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
29374000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
203224000 usd
CY2023Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
545848000 usd
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
47890000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
271253000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
7112560000 usd
CY2023Q4 us-gaap Assets
Assets
16893578000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
514533000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
828878000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
752598000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
394399000 usd
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
123299000 usd
CY2024Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
21268000 usd
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
28507000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2642214000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2330389000 usd
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
8268334000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
183074000 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
726217000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
15284063000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
14150228000 usd
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
1499288000 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
90000 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
295637000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1275301000 usd
CY2024Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
7508000 shares
CY2024Q3 us-gaap Treasury Stock Value
TreasuryStockValue
1021979000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-162334000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
386715000 usd
CY2024Q3 us-gaap Minority Interest
MinorityInterest
199948000 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
586663000 usd
CY2023Q4 dva Discount Premium And Deferred Financing Costs
DiscountPremiumAndDeferredFinancingCosts
54347000 usd
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
8391633000 usd
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
123299000 usd
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
8268334000 usd
dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
88824000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
90132000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
88824000 shares
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
dva Corporate Integrity Agreement Period
CorporateIntegrityAgreementPeriod
P5Y
CY2024Q3 us-gaap Other Income
OtherIncome
125029000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
534878000 usd
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85795000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88422000 shares
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
32756000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2939620000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
38445000 usd
CY2024Q3 us-gaap Assets
Assets
17503737000 usd
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
82624000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
88824000 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
89000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
509804000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
598288000 usd
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
0 shares
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-52084000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1056097000 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
187965000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1244062000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17503737000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16893578000 usd
us-gaap Profit Loss
ProfitLoss
901492000 usd
us-gaap Profit Loss
ProfitLoss
726406000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
549758000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
550166000 usd
dva Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
12527000 usd
dva Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
7132000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
82313000 usd
us-gaap Increase Decrease In Equity Securities Fv Ni
IncreaseDecreaseInEquitySecuritiesFvNi
-91100000 usd
us-gaap Increase Decrease In Equity Securities Fv Ni
IncreaseDecreaseInEquitySecuritiesFvNi
-40121000 usd
us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain
BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
35147000 usd
us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain
BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
0 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-20495000 usd
dva Increase Decrease In Other Current Receivables And Other Current Assets
IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets
-72477000 usd
dva Increase Decrease In Other Current Receivables And Other Current Assets
IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets
-31842000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
12858000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1101000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-43414000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-33837000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
27314000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
65279000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
35646000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
10822000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-7528000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-1878000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-7646000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-7945000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1474411000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1573826000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
384786000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
409011000 usd
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
161210000 usd
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
7990000 usd
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
17937000 usd
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
24907000 usd
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
15319000 usd
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
30419000 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
8784000 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
6693000 usd
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
22092000 usd
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
94414000 usd
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
4558000 usd
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
3930000 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
4497000 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
276006000 usd
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
6554000 usd
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
3364000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-523455000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-603504000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
6623634000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
2468335000 usd
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
5437907000 usd
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
2992248000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
46011000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
53466000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1020550000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Payments Of Distributions To Affiliates
PaymentsOfDistributionsToAffiliates
229236000 usd
us-gaap Payments Of Distributions To Affiliates
PaymentsOfDistributionsToAffiliates
203381000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
112496000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
41155000 usd
us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
10623000 usd
us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
11579000 usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
860000 usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
50962000 usd
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
40751000 usd
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
7875000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-251834000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-767249000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-5112000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3063000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
694010000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
206136000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
464634000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
338989000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1158644000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
545125000 usd
CY2024Q3 us-gaap Revenues
Revenues
3263590000 usd
CY2023Q3 us-gaap Revenues
Revenues
3121332000 usd
us-gaap Revenues
Revenues
8994400000 usd
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
58403000 usd
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
75949000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
214688000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
246632000 usd
us-gaap Net Income Loss
NetIncomeLoss
677013000 usd
us-gaap Net Income Loss
NetIncomeLoss
540870000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
83721000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
91322000 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
86123000 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
90937000 shares
CY2024Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2074000 shares
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2719000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2299000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2380000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85795000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94041000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88422000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93317000 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.56
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.70
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
7.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.95
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.50
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.80
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11000 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
271000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
135000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
615000 shares
CY2024Q3 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
15296000 usd
CY2024Q3 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
39544000 usd
CY2024Q3 us-gaap Marketable Securities
MarketableSecurities
54840000 usd
CY2023Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
22109000 usd
CY2023Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
37391000 usd
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
59500000 usd
CY2024Q3 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
15296000 usd
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
20996000 usd
CY2023Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
7110000 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
11610000 usd
CY2024Q3 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
0 usd
CY2024Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
33844000 usd
CY2023Q4 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
14999000 usd
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
47890000 usd
CY2024Q3 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
15296000 usd
CY2024Q3 us-gaap Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
39544000 usd
CY2024Q3 us-gaap Marketable Securities
MarketableSecurities
54840000 usd
CY2023Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
22109000 usd
CY2023Q4 us-gaap Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
37391000 usd
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
59500000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
7076610000 usd
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
26083000 usd
CY2023 us-gaap Goodwill Translation And Purchase Accounting Adjustments
GoodwillTranslationAndPurchaseAccountingAdjustments
36310000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
7112560000 usd
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
139606000 usd
us-gaap Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
3193000 usd
us-gaap Goodwill Translation And Purchase Accounting Adjustments
GoodwillTranslationAndPurchaseAccountingAdjustments
-21343000 usd
CY2024Q3 us-gaap Goodwill
Goodwill
7227630000 usd
CY2024Q3 us-gaap Goodwill Gross
GoodwillGross
7377889000 usd
CY2024Q3 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
150259000 usd
CY2024Q3 us-gaap Goodwill
Goodwill
7227630000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2024Q3 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
430483000 usd
CY2023Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
545848000 usd
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
9623754000 usd
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
8445980000 usd
CY2024Q3 dva Discount Premium And Deferred Financing Costs
DiscountPremiumAndDeferredFinancingCosts
67168000 usd
CY2024Q3 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
9556586000 usd
CY2024Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
296255000 usd
CY2024Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
9260331000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
163416000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
177412000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
187944000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
204790000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
1924071000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
41185000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
6924936000 usd
CY2024Q2 dva Debt Prepayment Extinguishment And Modification Costs
DebtPrepaymentExtinguishmentAndModificationCosts
9732000 usd
CY2024Q3 dva Debt Prepayment Extinguishment And Modification Costs
DebtPrepaymentExtinguishmentAndModificationCosts
10081000 usd
CY2024Q3 dva Leverage Ratio Covenant
LeverageRatioCovenant
4.00
CY2024Q3 dva Leverage Ratio Covenant Through Jun302026
LeverageRatioCovenantThroughJun302026
5.00
CY2024Q3 dva Leverage Ratio Covenant After Jun302026
LeverageRatioCovenantAfterJun302026
4.50
CY2024Q3 dva Leverage Ratio Covenant After Jun302026 Subject To Increase During Four Fiscal Quarters Following A Material Acquisition
LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition
5.00
CY2024Q3 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0569
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0484
CY2024Q3 us-gaap Longterm Debt Weighted Average Interest Rate
LongtermDebtWeightedAverageInterestRate
0.0571
CY2024Q3 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
0.59
CY2024Q3 dva Long Term Debt Percentage Bearing Economically Fixed Interest Rate
LongTermDebtPercentageBearingEconomicallyFixedInterestRate
0.95
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">contingencies</span><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in a highly regulated industry and is a party to various lawsuits, demands, claims, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits, governmental investigations (which frequently arise from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits) and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violations of law) and other legal proceedings, including, without limitation, those described below. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. As of September 30, 2024 and December 31, 2023, the Company’s total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were immaterial. While these accruals reflect the Company’s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including, without limitation, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or may result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.</span></div><div style="margin-top:9pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Governmental Inquiries and Related Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2017 U.S. Attorney Colorado Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In November 2017, the U.S. Attorney’s Office, District of Colorado informed the Company of an investigation it was conducting into possible federal healthcare offenses involving DaVita Kidney Care, as well as several of the Company’s wholly-owned subsidiaries. In addition to DaVita Kidney Care, the matter included an investigation into DaVita Rx, DaVita Laboratory Services, Inc. (DaVita Labs), and RMS Lifeline Inc. (Lifeline). In each of August 2018, May 2019, and July 2021, the Company received a Civil Investigative Demand (CID) pursuant to the False Claims Act from the U.S. Attorney's Office relating to this investigation. In May 2020, the Company sold its interest in Lifeline, but the Company retained certain liabilities of the Lifeline business, including those related to this investigation. On May 6, 2024, the Company finalized and executed a settlement agreement with the government and the relator in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> matter that included a settlement amount of $34,487 for this matter. On May 7, 2024, the government notified the U.S. District Court, District of Colorado of its decision to intervene for purposes of settlement in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Kogod v. DaVita Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The government and the relator agreed to voluntarily dismiss all substantive claims in the matter, and, on July 18, 2024, the District Court dismissed all claims except for the relator’s statutory claim for expenses, attorney’s fees, and costs. The Company disputes the relator’s request for expenses, attorney’s fees, and costs, and intends to defend accordingly.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 U.S. Attorney New Jersey Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In March 2020, the U.S. Attorney’s Office, District of New Jersey served the Company with a subpoena and a CID relating to an investigation being conducted by that office and the U.S. Attorney’s Office, Eastern District of Pennsylvania. The subpoena and CID request information on several topics, including certain of the Company’s joint venture arrangements with physicians and physician groups, medical director agreements, and compliance with its five-year Corporate Integrity Agreement, the term of which expired October 22, 2019. In November 2022, the Company learned that, on April 1, 2022, the U.S. Attorney’s Office for the District of New Jersey notified the U.S. District Court for the District of New Jersey of its decision not to elect to intervene in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Doe v. DaVita Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and filed a Stipulation of Dismissal. On April 13, 2022, the U.S. District Court for the District of New Jersey dismissed the case without prejudice. On October 12, 2022, the U.S. Attorney’s Office for the Eastern District of Pennsylvania notified the U.S. District Court, Eastern District of Pennsylvania, of its decision not to elect to intervene at this time in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Bayne v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The court then unsealed an amended complaint, which alleges violations of federal and state False Claims Acts, by order dated October 14, 2022. On November 8, 2023, the private party relator filed a fourth amended complaint. On November 29, 2023, the Company filed a motion to dismiss the fourth amended complaint. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 California Department of Insurance Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In April 2020, the California Department of Insurance (CDI) sent the Company an Investigative Subpoena relating to an investigation being conducted by that office. CDI issued a superseding subpoena in September 2020 and an additional subpoena in September 2021. Those subpoenas request information on a number of topics, including but not limited to the Company’s communications with patients about insurance plans and financial assistance from the American Kidney Fund (AKF), analyses of the potential impact of patients’ decisions to change insurance providers, and documents relating to donations or contributions to the AKF. The Company is continuing to cooperate with CDI in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 District of Columbia Office of Attorney General Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In January 2023, the Office of the Attorney General for the District of Columbia issued a CID to the Company in connection with an antitrust investigation into the AKF. The CID covers the period from January 1, 2016 to the present. The CID requests information on a number of topics, including but not limited to the Company’s communications with the AKF, documents relating to donations to the AKF, and communications with patients, providers, and insurers regarding the AKF. The Company is cooperating with the government in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2024 Federal Trade Commission Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In April 2024, the Company received from the Federal Trade Commission (FTC) two CIDs in connection with an industry investigation under Section 5 of the Federal Trade Commission Act regarding the acquisition of Medical Director services and provision of dialysis services. The CIDs cover the period from January 1, 2016 to the present and generally seek information relating to restrictive covenants, such as non-competes, with physicians. The Company is cooperating with the government in this investigation.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and ongoing discussions with regulators and to develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company frequently is subject to other inquiries by state or federal government agencies, many of which relate to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaints filed by relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company’s reputation, required changes to the Company’s business practices, an impact on the Company's various relationships and/or contracts related to the Company's business, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, members of its board of directors or management, possible criminal penalties, any of which could have a material adverse effect on the Company.</span></div><div style="margin-top:9pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Antitrust Indictment and Putative Class Action Suit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On July 14, 2021, an indictment was returned by a grand jury in the U.S. District Court, District of Colorado against the Company and its former chief executive officer in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> alleging that purported agreements entered into by DaVita's former chief executive officer not to solicit senior-level employees violated Section 1 of the Sherman Act. On April 15, 2022, a jury returned a verdict in the Company’s favor, acquitting both the Company and its former chief executive officer on all counts. On April 20, 2022, the court entered judgments of acquittal and closed the case. On August 9, 2021, DaVita Inc. and its former chief executive officer were added as defendants in a consolidated putative class action complaint in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Outpatient Medical Center Employee Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. District Court, Northern District of Illinois. This class action complaint asserts that the defendants violated Section 1 of the Sherman Act and seeks to bring an action on behalf of certain groups of individuals employed by the Company between February 1, 2012 and January 5, 2021. On September 26, 2022, the court denied the Company's motion to dismiss. The Company disputes the allegations in the class action complaint, as well as the asserted violations of the Sherman Act, and intends to defend this action accordingly.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including, without limitation, contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as may be described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 8, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company’s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management’s attention and result in significant legal expense, and may result in the diversion of significant operational resources, may impact the Company's various relationships and/or contracts related to the Company's business or otherwise harm the Company’s business, results of operations, financial condition, cash flows or reputation.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div>
CY2019Q4 dva Corporate Integrity Agreement Expiration Date
CorporateIntegrityAgreementExpirationDate
2019-10-22
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
154712000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y3M18D
CY2021Q4 srt Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
2000000000 usd
CY2024Q3 srt Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
2000000000 usd
CY2024Q3 us-gaap Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount
BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
61506000 usd
CY2024Q3 dva Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average Ebitda Multiple
PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple
220000000 usd
CY2024Q3 us-gaap Revenues
Revenues
3263590000 usd
CY2023Q3 us-gaap Revenues
Revenues
3121332000 usd
us-gaap Revenues
Revenues
9520867000 usd
us-gaap Revenues
Revenues
8994400000 usd
CY2024Q3 dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
28504000 usd
CY2023Q3 dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
41294000 usd
dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
84090000 usd
dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
99745000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
534878000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
495939000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
1525121000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
1212875000 usd
CY2024Q3 us-gaap Interest And Debt Expense
InterestAndDebtExpense
134583000 usd
CY2023Q3 us-gaap Interest And Debt Expense
InterestAndDebtExpense
98080000 usd
us-gaap Interest And Debt Expense
InterestAndDebtExpense
331748000 usd
us-gaap Interest And Debt Expense
InterestAndDebtExpense
302361000 usd
CY2024Q3 dva Debt Prepayment Extinguishment And Modification Costs
DebtPrepaymentExtinguishmentAndModificationCosts
10081000 usd
CY2023Q3 dva Debt Prepayment Extinguishment And Modification Costs
DebtPrepaymentExtinguishmentAndModificationCosts
0 usd
dva Debt Prepayment Extinguishment And Modification Costs
DebtPrepaymentExtinguishmentAndModificationCosts
19813000 usd
dva Debt Prepayment Extinguishment And Modification Costs
DebtPrepaymentExtinguishmentAndModificationCosts
7962000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-16780000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-19650000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-56900000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14525000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
373434000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
378209000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1116660000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
888027000 usd
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
187014000 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
188423000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
549758000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
550166000 usd
us-gaap Segment Expenditure Addition To Long Lived Assets
SegmentExpenditureAdditionToLongLivedAssets
384786000 usd
us-gaap Segment Expenditure Addition To Long Lived Assets
SegmentExpenditureAdditionToLongLivedAssets
409011000 usd
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
dva-20240930_cal.xml Edgar Link unprocessable
0000927066-24-000179-index-headers.html Edgar Link pending
0000927066-24-000179-index.html Edgar Link pending
0000927066-24-000179.txt Edgar Link pending
0000927066-24-000179-xbrl.zip Edgar Link pending
dva-20240930.htm Edgar Link pending
dva-20240930.xsd Edgar Link pending
dva-20240930_g1.jpg Edgar Link pending
dva-93024ex31110xq.htm Edgar Link pending
dva-93024ex31210xq.htm Edgar Link pending
dva-93024ex32110xq.htm Edgar Link pending
dva-93024ex32210xq.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
dva-20240930_def.xml Edgar Link unprocessable
dva-20240930_lab.xml Edgar Link unprocessable
dva-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
dva-20240930_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending